ABPRO HOLDINGS INC (ABP) Stock Price & Overview
NASDAQ:ABP • US0008472021
Current stock price
The current stock price of ABP is 0.522 USD. Today ABP is down by -34.76%. In the past month the price decreased by -82.02%. In the past year, price decreased by -97.92%.
ABP Key Statistics
- Market Cap
- 1.42M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -24.36
- Dividend Yield
- N/A
ABP Stock Performance
ABP Stock Chart
ABP Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ABP. When comparing the yearly performance of all stocks, ABP is a bad performer in the overall market: 99.74% of all stocks are doing better.
ABP Earnings
ABP Forecast & Estimates
ABP Groups
Sector & Classification
ABP Financial Highlights
Over the last trailing twelve months ABP reported a non-GAAP Earnings per Share(EPS) of -24.36. The EPS decreased by -361.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1294.36% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ABP Ownership
ABP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.92 | 367.796B | ||
| AMGN | AMGEN INC | 15.32 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.79 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.94 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.34 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ABP
Company Profile
Abpro Holdings, Inc. operates as a capital pool company. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The company went IPO on 2022-01-14. The firm is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. The company plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Company Info
IPO: 2022-01-14
ABPRO HOLDINGS INC
6 St Johns Lane, Floor 5
New York City NEW YORK US
Employees: 11
Phone: 12488907200
ABPRO HOLDINGS INC / ABP FAQ
What does ABP do?
Abpro Holdings, Inc. operates as a capital pool company. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The company went IPO on 2022-01-14. The firm is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. The company plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
What is the stock price of ABPRO HOLDINGS INC today?
The current stock price of ABP is 0.522 USD. The price decreased by -34.76% in the last trading session.
What is the dividend status of ABPRO HOLDINGS INC?
ABP does not pay a dividend.
What is the ChartMill rating of ABPRO HOLDINGS INC stock?
ABP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the GICS sector and industry of ABP stock?
ABPRO HOLDINGS INC (ABP) operates in the Health Care sector and the Biotechnology industry.